Restart Life Sciences Corp. develops natural remedies for individuals on the autism spectrum. While the company has a solid liquidity position with a current ratio of 1.25 and no debt, its financial health raises concerns, highlighted by a negative ROE of -324.7% and ROA of -73.3%. The low market cap of $4.69M and recent price increase of 7.14% may indicate volatility or speculative interest, suggesting investors should be cautious. Overall, the company's innovative focus is promising, but financial instability poses significant risks.
Loading financial metrics...
Company is burning $82K per quarter with $262K in cash. Approximately 3.2 quarters of runway at current burn rate.
Company posted a loss of $-563K over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $329K over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)